Geneoscopy develops a noninvasive screening methodology for colorectal cancer by analyzing biomarkers present in stool samples. This approach enables early detection of the disease, improving patient outcomes and reducing the need for invasive diagnostic procedures.
Funding
$218.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BRFounders
Product
Problem
Colorectal cancer (CRC) screening rates are suboptimal due to the inconvenience and invasiveness of current methods like colonoscopies, leading to a significant number of preventable deaths each year. Over 40% of eligible patients do not undergo screening, contributing to CRC being the second deadliest cancer in the United States.
Solution
Geneoscopy is developing a noninvasive, stool-based screening test for colorectal cancer that utilizes a proprietary eukaryotic RNA (seRNA) technology platform. This approach analyzes biomarkers present in stool samples to detect CRC and advanced adenomas, enabling earlier diagnosis and intervention. By offering a convenient and accessible alternative to colonoscopies, Geneoscopy aims to improve screening rates and reduce the burden of CRC. The test is designed to be easily integrated into routine healthcare, providing both patients and providers with a valuable tool for gastrointestinal health management.
Target Audience
The primary target audience includes individuals eligible for colorectal cancer screening, as well as healthcare providers seeking noninvasive screening options to improve patient compliance and early detection rates.
Features
- Stool-based sample collection for noninvasive screening
- Proprietary eukaryotic RNA (seRNA) technology platform for biomarker analysis
- Detection of colorectal cancer and advanced adenomas
- Designed for convenient integration into routine healthcare workflows